Clinical trial
Irinotecan in Treating Patients With Recurrent Malignant Glioma
NCT00003301 · New Approaches to Brain Tumor Therapy Consortium, Other · Completed
Key facts
| NCT number | NCT00003301 |
|---|---|
| Title | Irinotecan in Treating Patients With Recurrent Malignant Glioma |
| Official title | A Dose Finding and Safety/Efficacy Trial of CPT-11 (Irinotecan) in Patients With Recurrent Malignant Gliomas |
| Lead sponsor | New Approaches to Brain Tumor Therapy Consortium, Other |
| Collaborators | National Cancer Institute (NCI) NIH |
| Status | Completed |
| Phase | Phase 1/Phase 2 |
| Study type | Interventional |
| Conditions | Brain and Central Nervous System Tumors |
| Intervention type | Drug |
| Interventions | irinotecan hydrochloride |
| Start date | Jul 1, 1998 |
| Completion | Apr 1, 2004 |
| First posted | Apr 9, 2004 |
| Last update posted | Jun 21, 2013 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: